Regulatory t-cell therapy
Regulatory t-cell therapy has been studied in 3 papers since 2024: none in people yet, 1 in animals, 2 reviews; 1 in the past year. The research so far is in animals. The newest paper, Feb 20, 2026: “Xeno kidney: revolutionizing kidney disease treatment”.
3 papers study it2 findingsUpdated
- 1 lab in 1 country
- Funders: Agencia Nacional de Promoción Científica y Tecnológica and 6 more
- Animals1
What did studies of Regulatory t-cell therapy find?
2Studies of Regulatory t-cell therapy measured 2 outcomes; the most studied are inflammation (1 study) and effectiveness (1).
Inflammation
downin mice1
1 study
Inflammation
downin mice1
Regulatory t-cell therapy decreases inflammation in mice (co-adoptive transfer into RAG1KO mice with CD25KO CD4+ T cells).
“in recipients of young B6 Tregs plus CD25KO CD4+ T cells, LGs had significantly reduced inflammation.”
Animalsco-adoptive transfer into RAG1KO mice with CD25KO CD4+ T cellslacrimal gland
Aged regulatory T cells fail to control autoimmune lacrimal gland pathogenic CD4⁺ T cells
GeroScience
Effectiveness
upin humans1
1 study
Effectiveness
upin humans1
Regulatory t-cell therapy improves effectiveness in humans (clinical trials).
“Clinical trials involving Tregs have demonstrated their safety and effectiveness.”
Reviewclinical trials
Bioactive materials